Astellas Pharma Shares Fall After Unveiling Five-Year Plan

Astellas Pharma Inc. announced a five-year plan and plans to seek European regulatory review for an experimental drug targeting menopausal hot flashes, leading to a decline in its shares. The company's headquarters is in Tokyo, Japan, and the initiative was mentioned by Yasukawa.